Fatigue News and Research

RSS

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.

27 Sep 2018

New drug to treat Parkinson's disease psychosis do not pose greater risk of death

In the wake of media and public reports about increased mortality linked to a new drug for treating Parkinson's disease psychosis -- a symptom of the progressive nervous system disorder in which patients experience hallucinations and delusions -- researchers at University of California San Diego School of Medicine conducted a retrospective study of qualifying patients in the UC San Diego Health system, concluding that the new drug, pimavanserin, did not pose a statistically significant greater risk of death.

27 Sep 2018

Third case of monkey pox confirmed in UK

Officials from Public Health England (PHE) have confirmed yesterday (26th September 2018) that a third person in UK has been diagnosed with monkey pox. While the first two patients had most likely picked up the infection from Nigeria, this third infection has occurred in a healthcare worker who was treating one of the first two infected patients at Blackpool Victoria Hospital.

26 Sep 2018

Researchers develop promising allergy vaccine for hay fever

Using sugar molecules researchers from the University of Copenhagen have developed a new vaccine for hay fever that may reduce treatment times and increase the effect of treatments.

26 Sep 2018

Biological 'switch' influences whether immature blood cells differentiate into red or white blood cells

Japanese scientists have revealed a biological "switch" that influences whether an immature blood cell would develop into a red blood cell or a subtype of white blood cell called myeloid cells in response to infection or inflammation within the body.

26 Sep 2018

Digital CBT can improve insomnia symptoms, daytime functioning and overall health

Treating insomnia with digital programs can improve insomnia symptoms, daytime functioning and overall health, a new study from the University of Oxford and Northwestern Medicine has found.

26 Sep 2018

Activation of glial cells causes inflammation in the brain of fibromyalgia patients

The causes of the difficult-to-treat pain syndrome fibromyalgia are largely unknown. Using PET brain imaging, researchers at Karolinska Institutet and Harvard University have now shown that glial cells - the central nervous system's immune cells - are activated in the brains of patients with fibromyalgia. The finding opens the way for new therapies

25 Sep 2018

Special Focus Issue takes wide view of complementary and integrative medicine in cancer

A Special Focus Issue on Integrative Oncology takes a wide-ranging view of the possible approaches and potential therapeutic benefits of complementary and integrative medicine in multiple age groups, nations, and special populations.

25 Sep 2018

Study: Optimizing dopaminergic treatment improves non-motor symptoms and quality of life

Non-motor symptoms are common in late-stage Parkinson's disease as the frequency and severity of most of these symptoms increase with advancing disease. Optimizing dopaminergic treatment in the most severe stages can affect non-motor symptoms and improve quality of life, report scientists in the Journal of Parkinson's Disease.

25 Sep 2018

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer presented on the press program of the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.

25 Sep 2018

Researchers find impact of neurobehavioral symptoms on employment in adults with TBI

Kessler Foundation researchers have published their findings linking behavioral symptoms with employment outcomes among adults with moderate to severe traumatic brain injury.

24 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

Researchers develop technology to study behavior of implants without animal testing

An international team of researchers consisting of scientists from NUST MISIS and TU Dortmund University has developed a technology to study the behavior of orthopedic implants in laboratory conditions as close as possible to the human body.

21 Sep 2018

$CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL$

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

AbbVie, a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for VENCLYXTO® in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who have received at least one prior therapy.

21 Sep 2018

Older individuals with multiple sclerosis report higher quality of life than younger counterparts

A recent brief report by MS researchers provides preliminary evidence that older individuals with multiple sclerosis report lower levels of depression and higher quality of life than their younger counterparts.

20 Sep 2018

More doctor visits can lower risk of suicide attempts in fibromyalgia patients

Fibromyalgia patients who regularly visit their physicians are much less likely to attempt suicide than those who do not, according to a new Vanderbilt University Medical Center study published in Arthritis Care & Research.

19 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

Processing speed important to higher order cognitive function in multiple sclerosis patients

A recent article by Kessler Foundation researchers underscores the importance of processing speed in overall cognitive function in individuals with multiple sclerosis and their performance of everyday life activities.

19 Sep 2018

Fatigue News and Research

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

New drug to treat Parkinson's disease psychosis do not pose greater risk of death

Third case of monkey pox confirmed in UK

Researchers develop promising allergy vaccine for hay fever

Biological 'switch' influences whether immature blood cells differentiate into red or white blood cells

Digital CBT can improve insomnia symptoms, daytime functioning and overall health

Activation of glial cells causes inflammation in the brain of fibromyalgia patients

Special Focus Issue takes wide view of complementary and integrative medicine in cancer

Study: Optimizing dopaminergic treatment improves non-motor symptoms and quality of life

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Researchers find impact of neurobehavioral symptoms on employment in adults with TBI

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Researchers develop technology to study behavior of implants without animal testing

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

Older individuals with multiple sclerosis report higher quality of life than younger counterparts

More doctor visits can lower risk of suicide attempts in fibromyalgia patients

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Processing speed important to higher order cognitive function in multiple sclerosis patients

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News